CR20160293A - Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina - Google Patents

Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina

Info

Publication number
CR20160293A
CR20160293A CR20160293A CR20160293A CR20160293A CR 20160293 A CR20160293 A CR 20160293A CR 20160293 A CR20160293 A CR 20160293A CR 20160293 A CR20160293 A CR 20160293A CR 20160293 A CR20160293 A CR 20160293A
Authority
CR
Costa Rica
Prior art keywords
rosuvastatin
oral administration
ezetimibe
administration including
composite formulation
Prior art date
Application number
CR20160293A
Other languages
English (en)
Inventor
Yong Il Kim
Seung Jun Lee
Jae Hyun Park
Jin Cheul Kim
Jung Hyun Cho
Jong Soo Woo
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53791740&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20160293(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of CR20160293A publication Critical patent/CR20160293A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona una formulacion compuesta solida para administracion oral, incluyendo la formulacion compuesta solida: una parte de granulos de ezetimibe, que incluye ezetimibe, teniendo dicho ezetimibe una distribucion de tamanos de particulas en la que el tamano medio de particulas d(0.9) para el 90% inferior es alrededor de 10 µm o menos; y una parte de mezcla de rosuvastatina, que incluye rosuvastatina o una sal farmaceuticamente aceptable de la misma, y un metodo para preparar la formulacion compuesta.
CR20160293A 2013-12-30 2014-12-30 Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina CR20160293A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20130167156 2013-12-30
KR1020140071081A KR20150079373A (ko) 2013-12-30 2014-06-11 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
PCT/KR2014/013087 WO2015102400A1 (en) 2013-12-30 2014-12-30 Composite formulation for oral administration comprising ezetimibe and rosuvastatin

Publications (1)

Publication Number Publication Date
CR20160293A true CR20160293A (es) 2016-10-05

Family

ID=53791740

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20160293A CR20160293A (es) 2013-12-30 2014-12-30 Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina

Country Status (25)

Country Link
US (1) US10434067B2 (es)
EP (1) EP3089739A4 (es)
JP (1) JP2017500303A (es)
KR (2) KR20150079373A (es)
CN (1) CN105873571B (es)
AR (1) AR098996A1 (es)
AU (1) AU2014374552B2 (es)
CA (1) CA2933178A1 (es)
CL (1) CL2016001654A1 (es)
CR (1) CR20160293A (es)
DO (1) DOP2016000159A (es)
GT (1) GT201600137A (es)
MX (1) MX2016008725A (es)
MY (1) MY187637A (es)
NI (1) NI201600093A (es)
PE (1) PE20161072A1 (es)
PH (1) PH12016501196A1 (es)
RU (1) RU2683937C2 (es)
SG (1) SG10201805657PA (es)
SV (1) SV2016005236A (es)
TW (1) TWI655944B (es)
UA (1) UA117685C2 (es)
UY (1) UY35932A (es)
WO (1) WO2015102400A1 (es)
ZA (1) ZA201603934B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA43114A (fr) 2015-10-30 2018-09-05 Cancer Prevention Pharmaceuticals Inc Formulation combinée à dose fixe d'éflornithine et sulindac
EP3243506A1 (en) 2016-05-09 2017-11-15 Adamed sp. z o.o. Pharmaceutical composition
JP2017210455A (ja) * 2016-05-27 2017-11-30 ニプロ株式会社 エゼチミブ含有医薬組成物
CZ2016538A3 (cs) 2016-09-05 2018-03-14 Zentiva, K.S. Farmaceutická kompozice obsahující dvě rozdílné účinné látky
CZ2016539A3 (cs) 2016-09-05 2018-03-14 Zentiva, K.S. Farmaceutická kompozice obsahující dvě rozdílné účinné látky a způsob její přípravy
KR101910902B1 (ko) * 2016-11-03 2018-10-24 한미약품 주식회사 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합제제
KR102206535B1 (ko) * 2016-11-29 2021-01-22 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합정제
JP6848469B2 (ja) * 2017-01-20 2021-03-24 ニプロ株式会社 エゼチミブ含有医薬組成物の製造方法
JP7115825B2 (ja) * 2017-06-28 2022-08-09 日医工株式会社 エゼチミブ含有経口製剤及びその製造方法
JP2019014700A (ja) * 2017-07-11 2019-01-31 大原薬品工業株式会社 エゼチミブ含有口腔内崩壊錠及びその製造方法
JP6937195B2 (ja) * 2017-09-01 2021-09-22 興和株式会社 医薬組成物
KR102569271B1 (ko) * 2018-03-19 2023-08-23 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 약제학적 복합제제
GR1009727B (el) * 2018-11-28 2020-04-14 Elpen Αε Φαρμακευτικη Βιομηχανια Μονολιθικη σταθερη φαρμακοτεχνικη μορφη ταχειας αποδεσμευσης εζετιμιμπης και ροσουβαστατινης
BR112022001783A2 (pt) * 2019-07-31 2022-03-22 Tecnimede Sociedade Tecnico Medicinal Sa Composições orais sólidas multiunitárias de liberação imediata, seus métodos e usos.
BR112023003323A2 (pt) * 2020-08-25 2023-03-21 Daewoong Pharmaceutical Co Ltd Composição farmacêutica em forma de dosagem única
JP2022104836A (ja) * 2020-12-29 2022-07-11 日本ジェネリック株式会社 エゼチミブ及びロスバスタチンを含む錠剤
CN112999178A (zh) * 2021-03-01 2021-06-22 乐普制药科技有限公司 一种依折麦布匹伐他汀钙复方双层片剂
GB2622822A (en) * 2022-09-28 2024-04-03 Novumgen Ltd A rapidly disintegrating tablet of rosuvastatin and its process of preparation

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
PT634175E (pt) 1993-07-15 2001-06-29 Hoffmann La Roche Combinacao farmaceutica que contem um inibidor do sistema renina-angiotensina e o antagonista de endotelina
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
ES2287826T3 (es) 2000-12-20 2007-12-16 Schering Corp 2-azetidinonas sustituidas con hidroxi utiles como agentes hipocolesterolemicos.
HU230253B1 (hu) 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
RS11104A (sr) 2001-08-22 2006-12-15 Sanofi Aventis Deutschland Gmbh. Kombinovani preparati derivata 1,4-benzotiepin-1,1-dioksida sa drugim aktivnim supstancama i njihova primena
EP1648422A4 (en) 2003-07-28 2007-09-19 Reddys Lab Inc Dr TREATMENT AND PREVENTION OF CARDIOVASCULAR ACCIDENTS
BRPI0609614A2 (pt) 2005-04-04 2010-04-20 Univ Pontificia Catolica Chile uso de ezetimiba na prevenção e tratamento de litìases de colesterol na árvore biliar
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US20070275052A1 (en) * 2006-05-24 2007-11-29 Glenmark Pharmaceuticals Limited Pharmaceutical compositions containing sterol inhibitors
EA017349B1 (ru) 2007-01-24 2012-11-30 Крка Способ получения эзетимиба и его производных
WO2008101723A2 (en) 2007-02-23 2008-08-28 Krka Pharmaceutical composition containing a cholesterol absorption inhibitor
EP2182925A2 (en) * 2007-07-27 2010-05-12 Cipla Limited Pharmaceutical compositions and process for making them
WO2009024889A2 (en) * 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
JP5566288B2 (ja) 2008-05-30 2014-08-06 武田薬品工業株式会社 複素環化合物
AU2008358622A1 (en) 2008-06-27 2009-12-30 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of rosuvastatin calcium
ES2382773T3 (es) * 2009-03-13 2012-06-13 Sanovel Ilac Sanayi Ve Ticaret A.S. Composiciones de ezetimiba
US20110196383A1 (en) 2009-05-05 2011-08-11 Atherolysis Medical, Inc Atherosclerotic Plaque Dissolution Composition
WO2011019326A2 (en) 2009-07-02 2011-02-17 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation
TR201009397A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Rosuvastatin içeren farmasötik bileşimler.
WO2011139256A2 (en) * 2010-05-04 2011-11-10 Bilgic Mahmut Stable rosuvastatin formulations
KR101248804B1 (ko) * 2010-05-14 2013-03-29 한미사이언스 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제
EP2468258A1 (en) * 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
WO2013066279A1 (en) * 2011-10-13 2013-05-10 Mahmut Bilgic Solid dosage forms comprising ezetimibe
ES2802252T3 (es) * 2012-05-01 2021-01-18 Althera Life Sciences Llc Formulación de comprimido oral que consiste en la combinación fija de rosuvastatina y ezetimiba para el tratamiento de hiperlipidemia y enfermedades cardiovasculares
KR101335365B1 (ko) * 2012-05-22 2013-12-02 건일제약 주식회사 오메가-3 지방산 또는 그의 알킬 에스테르 및 스타틴계 약물을 함유하는 다층코팅 형태의 경구투여용 약학 조성물
MX2012014970A (es) * 2012-12-18 2013-08-27 Hetlabs Mexico S A De C V Composiciones farmaceuticas que comprenden ezetimiba y rosuvastatina de calcio amorfo novedoso.
KR102240429B1 (ko) * 2013-05-06 2021-04-15 한미약품 주식회사 로수바스타틴 또는 이의 약학적으로 허용되는 염이 함유된 필름 코팅층을 포함하는 복합 제형

Also Published As

Publication number Publication date
PH12016501196B1 (en) 2016-08-15
TW201609091A (zh) 2016-03-16
CA2933178A1 (en) 2015-07-09
AU2014374552A1 (en) 2016-06-02
NI201600093A (es) 2016-07-22
EP3089739A1 (en) 2016-11-09
US20160346213A1 (en) 2016-12-01
UA117685C2 (uk) 2018-09-10
MX2016008725A (es) 2017-02-28
KR20150079373A (ko) 2015-07-08
PH12016501196A1 (en) 2016-08-15
RU2016123828A (ru) 2018-02-07
ZA201603934B (en) 2017-09-27
AU2014374552B2 (en) 2019-09-19
RU2016123828A3 (es) 2018-08-28
PE20161072A1 (es) 2016-11-04
EP3089739A4 (en) 2017-08-02
DOP2016000159A (es) 2016-12-15
CN105873571B (zh) 2019-10-22
CN105873571A (zh) 2016-08-17
WO2015102400A1 (en) 2015-07-09
MY187637A (en) 2021-10-05
GT201600137A (es) 2018-10-19
UY35932A (es) 2015-07-31
SG10201805657PA (en) 2018-08-30
CL2016001654A1 (es) 2017-01-06
AR098996A1 (es) 2016-06-22
JP2017500303A (ja) 2017-01-05
KR20150079454A (ko) 2015-07-08
TWI655944B (zh) 2019-04-11
RU2683937C2 (ru) 2019-04-03
SV2016005236A (es) 2016-11-03
US10434067B2 (en) 2019-10-08

Similar Documents

Publication Publication Date Title
CR20160293A (es) Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina
JOP20150154B1 (ar) صيغة مادة مركبة للإعطاء عن طريق الفم تشتمل على إزيتمايب ورسيوفاستاتين وعملية تحضيرها
AR077629A1 (es) Mimetico de smac
AR091233A1 (es) Composicion farmaceutica que comprende abediterol
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
MX2015010829A (es) Compuestos terapeuticos y sus usos.
GT201700124A (es) Formulación de relación fija de insulina glargina/lixisenatida
CL2015003468A1 (es) Composicion solida para administracion oral conteniendo acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.
AR090975A1 (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamida
HK1217333A1 (zh) 喹唑啉衍生物的固態形式及其作爲braf抑制劑的用途
EA201401309A1 (ru) Фармацевтическая композиция для ингаляции, содержащая аклидиний, и её применение
PL408608A1 (pl) Trwała stała kompozycja farmaceutyczna cytyzyny oraz sposób jej wytwarzania
PH12014502407B1 (en) New alfentanil composition for the treatment of acute pain
AU2014226192A8 (en) Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles
CL2015002702A1 (es) Composiciones farmacéuticas micronizadas.
MX2012013178A (es) Composicion antiparasitaria de amplio espectro de nitazoxanida, probioticos y prebioticos.
CL2019001424A1 (es) Comprimido compuesto oral que comprende ezetimiba y rosuvastatina.
MX385513B (es) Composiciones farmaceuticas que comprenden safinamida.
GEP201706672B (en) Dry powder inhaler compositions comprising long acting muscorinic antagonists
CL2015001940A1 (es) Formulación que comprende un compuesto de benzotiazolona.
WO2013111013A3 (en) Methods for treating alzheimer's disease by administering certain synthetic compounds
PE20170201A1 (es) Formas de dosificacion farmaceutica
IN2013MU03428A (es)
AR089764A1 (es) Composicion farmaceutica de administracion oral de nitazoxanida, util para el tratamiento de infecciones parasitarias intestinales, y proceso para preparar granulos para suspension de nitazoxanida
BR112014031846A2 (pt) redução do tamanho de partículas